當(dāng)前位置：首頁(yè) JCRQ1 期刊介紹(非官網(wǎng))

Advanced Drug Delivery ReviewsSCIE

國(guó)際簡(jiǎn)稱：ADV DRUG DELIVER REV 參考譯名：先進(jìn)的藥物輸送審查

中科院分區(qū)
1區(qū)
CiteScore分區(qū)
Q1
JCR分區(qū)
Q1

基本信息：: ISSN：0169-409X; E-ISSN：1872-8294; 是否OA：未開放; 是否預(yù)警：否; TOP期刊：是

出版信息：: 出版地區(qū)：NETHERLANDS; 出版商：Elsevier; 出版語(yǔ)言：English; 出版周期：Monthly; 出版年份：1987; 研究方向：藥學(xué)-醫(yī)學(xué)

評(píng)價(jià)信息：: 影響因子：15.2; H-index：278; CiteScore指數(shù)：28.1; SJR指數(shù)：3.411; SNIP指數(shù)：2.46

發(fā)文數(shù)據(jù)：: Gold OA文章占比：31.54%; 研究類文章占比：0.57%; 年發(fā)文量：174; 自引率：0.0496...; 開源占比：0.1785; 出版撤稿占比：0; 出版國(guó)人文章占比：0.07; OA被引用占比：0.0807...

投稿咨詢加急見刊

英文簡(jiǎn)介期刊介紹 CiteScore數(shù)據(jù) 中科院SCI分區(qū) JCR分區(qū) 發(fā)文數(shù)據(jù) 常見問題

英文簡(jiǎn)介Advanced Drug Delivery Reviews期刊介紹

The aim of the Journal is to provide a forum for the critical analysis of advanced drug and gene delivery systems and their applications in human and veterinary medicine. The Journal has a broad scope, covering the key issues for effective drug and gene delivery, from administration to site-specific delivery.

In general, the Journal publishes review articles in a Theme Issue format. Each Theme Issue provides a comprehensive and critical examination of current and emerging research on the design and development of advanced drug and gene delivery systems and their application to experimental and clinical therapeutics. The goal is to illustrate the pivotal role of a multidisciplinary approach to modern drug delivery, encompassing the application of sound biological and physicochemical principles to the engineering of drug delivery systems to meet the therapeutic need at hand. Importantly the Editorial Team of ADDR asks that the authors effectively window the extensive volume of literature, pick the important contributions and explain their importance, produce a forward looking identification of the challenges facing the field and produce a Conclusions section with expert recommendations to address the issues.

Articles review the current status of a specific topic, giving equal emphasis to the identification of major conceptual and technological challenges to successful drug and gene delivery, to an evaluation of triumphs as well as shortcomings in current conceptual and technical approaches, and to a discussion of their possible solution.

期刊簡(jiǎn)介Advanced Drug Delivery Reviews期刊介紹

《Advanced Drug Delivery Reviews》自1987出版以來，是一本醫(yī)學(xué)優(yōu)秀雜志。致力于發(fā)表原創(chuàng)科學(xué)研究結(jié)果，并為醫(yī)學(xué)各個(gè)領(lǐng)域的原創(chuàng)研究提供一個(gè)展示平臺(tái)，以促進(jìn)醫(yī)學(xué)領(lǐng)域的的進(jìn)步。該刊鼓勵(lì)先進(jìn)的、清晰的闡述，從廣泛的視角提供當(dāng)前感興趣的研究主題的新見解，或?qū)彶槎嗄陙砟硞€(gè)重要領(lǐng)域的所有重要發(fā)展。該期刊特色在于及時(shí)報(bào)道醫(yī)學(xué)領(lǐng)域的最新進(jìn)展和新發(fā)現(xiàn)新突破等。該刊近一年未被列入預(yù)警期刊名單，目前已被權(quán)威數(shù)據(jù)庫(kù)SCIE收錄，得到了廣泛的認(rèn)可。

該期刊投稿重要關(guān)注點(diǎn)：

預(yù)計(jì)審稿時(shí)間：一般,3-8周約15.1周
國(guó)際TOP期刊
醫(yī)學(xué)
PHARMACOLOGY & PHARMACY
SCIE
中科院1區(qū)
非預(yù)警

Cite Score數(shù)據(jù)（2024年最新版）Advanced Drug Delivery Reviews Cite Score數(shù)據(jù)

CiteScore：28.1
SJR：3.411
SNIP：2.46

學(xué)科類別	分區(qū)	排名	百分位
大類：Pharmacology, Toxicology and Pharmaceutics 小類：Pharmaceutical Science	Q1	1 / 183	99%

CiteScore 是由Elsevier(愛思唯爾)推出的另一種評(píng)價(jià)期刊影響力的文獻(xiàn)計(jì)量指標(biāo)。反映出一家期刊近期發(fā)表論文的年篇均引用次數(shù)。CiteScore以Scopus數(shù)據(jù)庫(kù)中收集的引文為基礎(chǔ)，針對(duì)的是前四年發(fā)表的論文的引文。CiteScore的意義在于，它可以為學(xué)術(shù)界提供一種新的、更全面、更客觀地評(píng)價(jià)期刊影響力的方法，而不僅僅是通過影響因子(IF)這一單一指標(biāo)來評(píng)價(jià)。

歷年Cite Score趨勢(shì)圖

中科院SCI分區(qū)Advanced Drug Delivery Reviews 中科院分區(qū)

中科院 2023年12月升級(jí)版 綜述期刊：是 Top期刊：是

大類學(xué)科	分區(qū)	小類學(xué)科	分區(qū)
醫(yī)學(xué)	1區(qū)	PHARMACOLOGY & PHARMACY 藥學(xué)	1區(qū)

中科院分區(qū)表 是以客觀數(shù)據(jù)為基礎(chǔ)，運(yùn)用科學(xué)計(jì)量學(xué)方法對(duì)國(guó)際、國(guó)內(nèi)學(xué)術(shù)期刊依據(jù)影響力進(jìn)行等級(jí)劃分的期刊評(píng)價(jià)標(biāo)準(zhǔn)。它為我國(guó)科研、教育機(jī)構(gòu)的管理人員、科研工作者提供了一份評(píng)價(jià)國(guó)際學(xué)術(shù)期刊影響力的參考數(shù)據(jù)，得到了全國(guó)各地高校、科研機(jī)構(gòu)的廣泛認(rèn)可。

中科院分區(qū)表 將所有期刊按照一定指標(biāo)劃分為1區(qū)、2區(qū)、3區(qū)、4區(qū)四個(gè)層次，類似于“優(yōu)、良、及格”等。最開始，這個(gè)分區(qū)只是為了方便圖書管理及圖書情報(bào)領(lǐng)域的研究和期刊評(píng)估。之后中科院分區(qū)逐步發(fā)展成為了一種評(píng)價(jià)學(xué)術(shù)期刊質(zhì)量的重要工具。

歷年中科院分區(qū)趨勢(shì)圖

JCR分區(qū)Advanced Drug Delivery Reviews JCR分區(qū)

2023-2024 年最新版

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	4 / 354	99%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：PHARMACOLOGY & PHARMACY	SCIE	Q1	7 / 354	98.16%

JCR分區(qū)的優(yōu)勢(shì)在于它可以幫助讀者對(duì)學(xué)術(shù)文獻(xiàn)質(zhì)量進(jìn)行評(píng)估。不同學(xué)科的文章引用量可能存在較大的差異，此時(shí)單獨(dú)依靠影響因子(IF)評(píng)價(jià)期刊的質(zhì)量可能是存在一定問題的。因此，JCR將期刊按照學(xué)科門類和影響因子分為不同的分區(qū)，這樣讀者可以根據(jù)自己的研究領(lǐng)域和需求選擇合適的期刊。

歷年影響因子趨勢(shì)圖

發(fā)文數(shù)據(jù)

2023-2024 年國(guó)家/地區(qū)發(fā)文量統(tǒng)計(jì)

國(guó)家/地區(qū)數(shù)量
USA197
CHINA MAINLAND47
Australia43
England38
GERMANY (FED REP GER)38
France30
Netherlands27
Japan26
Canada17
Denmark15

本刊中國(guó)學(xué)者近年發(fā)表論文

1、Advances in image-guided drug delivery for antibacterial therapy
Author: Huang, Haiyan; Ali, Arbab; Liu, Yi; Xie, Hui; Ullah, Sana; Roy, Shubham; Song, Zhiyong; Guo, Bing; Xu, Jian

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2023; Vol. 192, Issue , pp. -. DOI: 10.1016/j.addr.2022.114634
2、Design strategies and applications of smart optical probes in the second near-infrared window
Author: Chang, Baisong; Chen, Jie; Bao, Jiasheng; Dong, Kangfeng; Chen, Si; Cheng, Zhen

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2023; Vol. 192, Issue , pp. -. DOI: 10.1016/j.addr.2022.114637
3、Radiation-assisted strategies provide new perspectives to improve the nanoparticle delivery to tumor
Author: Zhang, Dongxiao; He, Jian; Zhou, Min

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2023; Vol. 193, Issue , pp. -. DOI: 10.1016/j.addr.2022.114642
4、Nanomaterials and nanomaterials-based drug delivery to promote cutaneous wound healing
Author: Liu, Tengfei; Lu, Yifei; Zhan, Rixing; Qian, Wei; Luo, Gaoxing

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2023; Vol. 193, Issue , pp. -. DOI: 10.1016/j.addr.2022.114670
5、Role of wound microbiome, strategies of microbiota delivery system and clinical management
Author: Tang, Qinghan; Xue, Nannan; Ding, Xiaofeng; Tsai, Kevin H. -Y.; Hew, Jonathan J.; Jiang, Ruihan; Huang, Rizhong; Cheng, Xuxi; Ding, Xiaotong; Cheng, Yuen Yee; Chen, Jun; Wang, Yiwei

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2023; Vol. 192, Issue , pp. -. DOI: 10.1016/j.addr.2022.114671
6、Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy
Author: Sun, Yinping; Sha, Yongjie; Cui, Guanhong; Meng, Fenghua; Zhong, Zhiyuan

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2023; Vol. 192, Issue , pp. -. DOI: 10.1016/j.addr.2022.114624
7、Nanosensitizer-mediated unique dynamic therapy tactics for effective inhibition of deep tumors
Author: Sun, Wenjing; Chu, Chengchao; Li, Shi; Ma, Xiaoqian; Liu, Peifei; Chen, Shileng; Chen, Hongmin

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2023; Vol. 192, Issue , pp. -. DOI: 10.1016/j.addr.2022.114643
8、Protein encapsulation of nanocatalysts: A feasible approach to facilitate catalytic theranostics
Author: Jin, Duo; Liu, Manman; Zhang, Meng; Yu, Wenxin; Yu, Jiaji; Shen, Aizong; Cheng, Junjie; Liu, Yangzhong

Journal: ADVANCED DRUG DELIVERY REVIEWS. 2023; Vol. 192, Issue , pp. -. DOI: 10.1016/j.addr.2022.114648